Our Businesses

With major facilities in Australia, Germany, Switzerland and the U.S., CSL has over 10,000 employees working in 27 countries.
Use Contact CSL to find your nearest CSL business

Chart depicts the business structure of CSL Limited

For many serious and life-saving medical products, we are a partner of choice for many companies around the world.

Headquarters in Melbourne Australia, the CSL Group includes:


Key business areas

Research and Development

In 2006/07, we invested over AUD$190m in this part of our business. Our centres of excellence are located around the world and they focus on:
  • Developing new products
  • Improving existing products
Find out more about Research & Development

Plasma products

CSL is a leading manufacturer in a US$7.5 billion plasma industry. A continual focus on innovation in new products, improved products and manufacturing know how is the key to future growth.

The key businesses involved with plasma products include:
  • CSL Behring is a global provider of plasma-derived & recombinant products. We operate one of the world's largest plasma collection networks through CSL Plasma
  • CSL Behring is the chosen national plasma fractionator of Australia, New Zealand, Hong Kong, Malaysia, Singapore and Taiwan.  

Vaccines and pharmaceuticals

CSL is also a major manufacturer in a US$2 billion influenza industry, with 40 years manufacturing experience and sales spanning 27 countries around the globe.

In addition to providing influenza vaccines worldwide, bioCSL manufactures, sells and distributes a comprehensive range of vaccines, antivenoms and other pharmaceutical products in Australia and New Zealand. We also manufacture and market in vitro diagnostic products through Immunohaematology.


*In December 2012, CSL announced that its plasma product operations in Australia will take on the name of its global plasma business, CSL Behring, and that the Company’s vaccine, pharmaceutical and diagnostics business will operate under the newly created name of bioCSL, effective 1 January 2013.

LinkedIn Twitter Facebook Google+